Live Breaking News & Updates on சையத் யௌசுப் ஸ்யாஃபார்

email article
Launch prices of cancer drugs over the last decade were substantially higher in the U.S. than in similar, high-income European countries, and the gap only increased in the years after approval, according to an economic analysis.
From 2009 to 2019, the median monthly treatment costs for new drugs at launch reached $11,755 in the U.S., as compared to $8,305 in Germany, $6,955 in Switzerland, and $7,355 in England, reported Kerstin N. Vokinger, MD, JD, PhD, of the University of Zurich, and colleagues.
And, as described in
JAMA Oncology, prices were not necessarily associated with clinical benefits in any of the surveyed countries. ....

United States , North Carolina , Syed Yousuf Zafar , Kerstinn Vokinger , Mike Bassett , Elijahe Cummings , American Society Of Clinical Oncology , European Medicines Agency , Margolis Center , Health Policy At Duke University In Durham , University Of Zurich , Yousuf Zafar , Health Policy , Duke University , Medical Oncology , Clinical Benefit Scale , Clinical Oncology , Value Framework , Lower Drug Costs Now Act , ஒன்றுபட்டது மாநிலங்களில் , வடக்கு கரோலினா , சையத் யௌசுப் ஸ்யாஃபார் , மைக் பாசெட் , அமெரிக்கன் சமூகம் ஆஃப் மருத்துவ புற்றுநோயியல் , மார்கோலிஸ் மையம் , ஆரோக்கியம் பாலிஸீ இல் டியூக் பல்கலைக்கழகம் இல் டர்ஹாம் ,